ThermoGenesis Holdings Announces Financial Results for the Second Quarter Ended June 30, 2021, and Provides Corporate Update
ThermoGenesis Holdings (THMO) reported second-quarter 2021 results with net revenues of $2.2 million, stable year-over-year. AXP sales increased by 64% to $1.0 million, indicating a potential recovery in cord blood revenues. Gross profit rose to $1.0 million, or 45% of net revenues, due to a previous year’s inventory reserve expense. However, selling expenses increased by 77% to $3.5 million, and the net loss narrowed to $4.5 million, or ($0.38) per share. Cash and equivalents grew to $8.7 million. The company aims to expand into CDMO services for cell and gene therapies.
- AXP sales increased by 64% to $1.0 million, indicating potential market recovery.
- Gross profit improved to $1.0 million, representing 45% of net revenues.
- Net loss narrowed to $4.5 million from $6.4 million year-over-year.
- Selling, general, and administrative expenses rose by 77% to $3.5 million, driven by stock compensation.
- Sales from CAR-TXpress and other products decreased by $0.6 million.
RANCHO CORDOVA, Calif., Aug. 12, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2021 and provided a corporate strategic update.
"Cell and gene therapies are poised to continue to revolutionize many areas of medicine, and ThermoGenesis has been a pioneer in the development and commercialization of automated cell processing technologies that provide more efficient, higher-quality and cost-effective manufacturing solutions to move these therapies through the clinic and ultimately, to patients in need," stated Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis. "Throughout our 35-year history, we have leveraged the inherent flexibility of our proprietary technology platform to meet the ever-changing needs of the industry. Given the sheer volume of clinical trials currently underway in the CAR-T cell therapy field, alone, and the high manufacturing costs and serious capacity limitations of current cell-based contract development and manufacturing (CDMO) services, there remains a serious unmet need to bring these lifesaving therapies to market."
Dr. Xu continued, "Most of the existing players in the CDMO arena do not have proprietary manufacturing technologies which contributes to the market bottlenecks. To capitalize on the inefficiencies in the industry, we are committed to leveraging our high efficiency, semi-automated CAR-TXpress™ platform, which has been shown to reduce the manufacturing costs associated with CAR-T and other cell and gene therapies by up to
Financial Results for the Quarter Ended June 30, 2021
Net revenues. Net revenues for the quarter ended June 30, 2021, were
Gross profit. Gross profit for the quarter ended June 30, 2021, was
Selling, general and administrative expenses. Selling, general and administrative expenses were
Research and development expenses. Research and development expenses were
Interest Expense. Interest expense for the quarter ended June 30, 2021, was
Net loss. For the quarter ended June 30, 2021, the Company reported a comprehensive loss attributable to common stockholders of
Adjusted EBITDA. In addition to the results reported under US GAAP, the Company also uses a non-GAAP measure, Adjusted EBITDA, to evaluate operating performance and to facilitate the comparison of our historical results and trends. The Company uses the metric to determine operational cash flow. Adjusted EBITDA loss for the quarter ended June 30, 2021, was
Liquidity and Capital Resources. At June 30, 2021, the Company had cash and cash equivalents totaling
Conference Call and Webcast Information
ThermoGenesis will host a conference call today at 1:30 p.m. PT/4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts.
A webcast replay will also be available on ThermoGenesis' website for three months, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts.
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. When used in this press release, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company, or its management are intended to identify such forward-looking statements. Actual results, performance or achievements could differ materially from the results expressed in or implied by these forward-looking statements. Readers should be aware of important factors that, in some cases, have affected, and in the future could affect, actual results to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. These factors include without limitation, the ability to obtain capital and other financing in the amounts and at the times needed to launch new products, market acceptance of new products, the nature and timing of regulatory approvals for both new products and existing products for which the Company proposes new claims, realization of forecasted revenues, expenses and income, initiatives by competitors, price pressures, failure to meet FDA regulated requirements governing the Company's products and operations (including the potential for product recalls associated with such regulations), risks associated with initiating manufacturing for new products, failure to meet Foreign Corrupt Practice Act regulations, legal proceedings, uncertainty associated with the COVID-19 pandemic, and other risk factors listed from time to time in our reports with the Securities and Exchange Commission ("SEC"), including, in particular, those set forth in ThermoGenesis Holdings' Form 10-K for the year ended December 31, 2020.
Company Contact:
Wendy Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
Financials
ThermoGenesis Holdings, Inc. | ||||||
Condensed Consolidated Balance Sheets | ||||||
June 30, 2021 | December 31, 2020 | |||||
(Unaudited) | ||||||
ASSETS | ||||||
Current assets: | ||||||
Cash and cash equivalents | ||||||
Accounts receivable, net | 1,242,000 | 1,382,000 | ||||
Inventories | 5,813,000 | 5,877,000 | ||||
Prepaid expenses and other current assets | 354,000 | 878,000 | ||||
Total current assets | 16,077,000 | 15,298,000 | ||||
Inventories, non-current | 2,227,000 | 1,221,000 | ||||
Equipment and leasehold improvements, net | 1,282,000 | 1,424,000 | ||||
Right-of-use operating lease assets, net | 654,000 | 730,000 | ||||
Goodwill | 781,000 | 781,000 | ||||
Other intangible assets, net | 1,334,000 | 1,358,000 | ||||
Other assets | 48,000 | 48,000 | ||||
Total assets | ||||||
LIABILITIES AND EQUITY | ||||||
Current liabilities: | ||||||
Accounts payable | ||||||
Other current liabilities | 10,791,000 | 4,777,000 | ||||
Total current liabilities | 11,911,000 | 6,143,000 | ||||
Long-term liabilities | 2,623,000 | 8,847,000 | ||||
ThermoGenesis Holdings, Inc. stockholders' equity | 8,050,000 | 5,800,000 | ||||
Noncontrolling interests | (181,000) | 70,000 | ||||
Total liabilities and equity | ||||||
ThermoGenesis Holdings, Inc. | |||||||
Condensed Consolidated Statements of Operations | |||||||
(Unaudited) | |||||||
Three Months Ended | Six Months Ended | ||||||
2021 | 2020 | 2021 | 2020 | ||||
Net revenues | |||||||
Cost of revenues | 1,215,000 | 4,874,000 | 2,024,000 | 6,582,000 | |||
Gross profit (loss) | 986,000 | (2,632,000) | 1,694,000 | (1,140,000) | |||
Expenses: | |||||||
Selling, general and administrative | 3,502,000 | 1,978,000 | 5,494,000 | 4,070,000 | |||
Research and development | 622,000 | 578,000 | 1,001,000 | 1,187,000 | |||
Total operating expenses | 4,124,000 | 2,556,000 | 6,495,000 | 5,257,000 | |||
Loss from operations | (3,138,000) | (5,188,000) | (4,801,000) | (6,397,000) | |||
Other expenses | |||||||
Interest expense | (1,524,000) | (1,314,000) | (3,043,000) | (4,845,000) | |||
Other income (expenses) | (10,000) | (8,000) | (11,000) | (11,000) | |||
Gain on extinguishment of debt | -- | -- | 652,000 | -- | |||
Total other expense | (1,534,000) | (1,322,000) | (2,402,000) | (4,856,000) | |||
Net loss | (4,672,000) | (6,510,000) | (7,203,000) | (11,253,000) | |||
Loss attributable to noncontrolling interests | (133,000) | (73,000) | (251,000) | (214,000) | |||
Net loss attributable to common stockholders | |||||||
ThermoGenesis Holdings, Inc. | |||
Condensed Consolidated Statements of Cash Flows | |||
(Unaudited) | |||
Six Months Ended June 30, | |||
2021 | 2020 | ||
Cash flows from operating activities: | |||
Net cash used in operating activities | |||
Cash flows from investing activities: | |||
Capital expenditures | (80,000) | (23,000) | |
Cash flows from financing activities: | |||
Proceeds from convertible promissory note-related party | -- | 4,287,000 | |
Payments on finance lease obligations | -- | (22,000) | |
Proceeds from issuance of common stock, net of expenses | 6,832,000 | 5,214,000 | |
Proceeds from the exercise of options, warrants and pre-funded warrants | -- | 1,683,000 | |
Proceeds from note payable | -- | 646,000 | |
Net cash provided by financing activities | 6,832,000 | 11,808,000 | |
Effects of foreign currency rate changes on cash and cash equivalents | (1,000) | (5,000) | |
Net increase (decrease) in cash, cash equivalents and restricted cash | 1,507,000 | 2,827,000 | |
Cash, cash equivalents and restricted cash at beginning of period | 7,161,000 | 4,157,000 | |
Cash, cash equivalents and restricted cash at end of period | |||
ThermoGenesis Holdings, Inc. | ||||||||||
Reconciliation of Adjusted EBITDA to Net Loss | ||||||||||
(Unaudited) | ||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||
2021 | 2020 | 2021 | 2020 | |||||||
Net loss | ||||||||||
Deduct: | ||||||||||
Interest expense | (1,524,000) | (1,314,000) | (3,043,000) | (4,845,000) | ||||||
Other expense | (10,000) | (8,000) | (11,000) | (11,000) | ||||||
Gain on extinguishment of debt | -- | -- | 652,000 | -- | ||||||
Loss from operations | ||||||||||
Add: | ||||||||||
Depreciation and amortization | 154,000 | 193,000 | 320,000 | 392,000 | ||||||
Stock-based compensation expense | 2,099,000 | 314,000 | 2,357,000 | 381,000 | ||||||
Adjusted EBITDA | ||||||||||
The Company defines adjusted EBITDA as income (or loss) from operations less, depreciation, amortization, stock compensation and impairment of intangible assets.
View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-announces-financial-results-for-the-second-quarter-ended-june-30-2021-and-provides-corporate-update-301354685.html
SOURCE ThermoGenesis Holdings, Inc.
FAQ
What were ThermoGenesis' net revenues for Q2 2021?
How did ThermoGenesis perform financially in Q2 2021?
What is the current cash position of ThermoGenesis?
What changes occurred in ThermoGenesis' AXP sales?
What are the future plans for ThermoGenesis regarding CDMO services?
